Acceleration of drug
development in JapanBridge between preclinical
study and clinical research

Over the past few years, patient-derived xenograft (PDX) models have garnered attention as a platform for screening with substantial ability to predict clinical efficacy. PDX models are tumor-bearing models created by directly transplanting tumors removed from patients into immunodeficient mice. Compared to the conventional models cultured in dish, PDX models have a significant advantage of retaining the original structures and genetic information of a patient’s tumor. When used to evaluate anticancer drugs, PDX models thus essentially reflect the real effects of treatment in an actual patient with cancer, and these models are expected to serve as an important system with which to evaluate anticancer drugs. J-PDX is a patient-derived xenograft model that the National Cancer Center is establishing and building up in order to accelerate the development of anticancer drugs in Japan.

※J-PDX is registered as trademark.